Eric Law is the Head of CMC Regulatory Affairs at Century Therapeutics. Before joining Century, Eric has held various roles in the Global Regulatory Sciences – CMC and Cell Therapy Development organizations at Bristol Myers Squibb (BMS) / Celgene, where he spearheaded the regulatory strategy and process development efforts for a number of complex cell-based immunotherapy products through IND and clinical development stages. Eric led the successful submission of the marketing authorization application (MAA) in Europe for Abecma, the first chimeric antigen receptor T (CAR-T) cell therapy for multiple myeloma, which was subsequently approved in 2021. Eric received his BS and MS in Biochemical / Chemical Engineering from Rutgers, the State University of New Jersey.
